Dr. Edio Zampaglione, Head of Global Medical Affairs and Outcomes Research at Organon and an OBGYN, discusses unintended pregnancies, the importance of starting conversations about birth control options with college-bound students, and a new study published in “Pediatrics” that shows that conversations with adolescents about sexual and reproductive health, other than puberty, aren’t routinely taking place during preventive care visits, even though 72% of 15-17-year-olds (and 78% of parents of 15-17-year-olds) consider discussions about methods of birth control important.
Dr. Edio Zampaglione graduated from Temple University School of Pharmacy in 1989 with Bachelor of Science, Pharmacy degree and worked in retail pharmacy for two years before attending Temple University School of Medicine. He graduated with his MD degree in 1995 and completed a residency in OB/GYN at Einstein Medical Center in Philadelphia in 1999. Dr. Zampaglione was in private practice in Morristown, NJ before starting a career in the pharmaceutical industry in 2001. He started at Organon Inc. as Medical Director and launched NuvaRing and Implanon. Dr. Zampaglione stayed with Schering-Plough for a short time after acquisition in 2007 and then joined Baxter. Following Baxter, he joined Bayer Pharmaceuticals in 2009 and shortly thereafter was promoted to VP, Therapeutic Area Head for numerous therapeutic areas including Neurology, Cardio-pulmonary, Diagnostic Imagine and Consumer Health, but always with a primary focus on women’s healthcare. Dr. Zampaglione joined Merck/Organon in October 2020 as Head of Global Medical Affairs and Outcomes Research.